After claiming its approval in Europe earlier this year, Abbott has secured the FDA’s go-ahead for its Volt pulsed field ablation system for irregular heart rhythms, a step forward in an | With the U.
I felt fine, but my Whoop data told a different story. Paying attention led to early detection and a successful treatment.
Abbott will soon enter the competitive U.S. pulsed field ablation (PFA) market, having just received FDA approval for its ...
Abbott (NYSE: ABT) announced today that the FDA approved its Volt pulsed field ablation (PFA) system to treat patients with ...
The FDA approved Abbott's Volt PFA System for atrial fibrillation, supported by VOLT-AF trial data showing strong safety and ...
Abbott received approval from the Food and Drug Administration for its Volt Pulsed Field Ablation System to treat atrial fibrillation. The medical technology company said Monday that it would soon ...
Two years after the U.S. FDA approved the first pulsed field ablation system, Abbott Laboratories finally got the regulatory nod for its Volt PFA system. Abbott follows Medtronic plc, Boston ...
An ongoing trial at the Medical University of South Carolina is looking for a breakthrough for patients dealing with heart ...
Congenital heart disease (CHD) management has evolved substantially over recent decades, with transcatheter and hybrid interventions now providing minimally ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback